Pegylated TRAIL retains anti-leukemic cytotoxicity and exhibits improved signal transduction activity with respect to TRAIL

Arianna Gonelli, Oriano Radillo, Sara Drioli, Erika Rimondi, Paola Secchiero, Gian Maria Bonora

Research output: Contribution to journalArticle

Abstract

To improve the pharmacokinetic profile of tumor necrosis factor-related apoptosis inducing ligand (TRAIL) an N-terminal specific pegylation was performed to generate pegylated TRAIL (PEG-TRAIL). In in vitro experiments, we found that although PEGTRAIL was slightly less efficient than recombinant TRAIL in promoting leukemic cell apoptosis, it showed an improved ability to promote migration of bonemarrow mesenchymal stem cells and to elicit the ERK1/2 intracellular signal transduction pathway. Overall, these data suggest that TRAIL pegylation retains, or even enhances, the biological activities of TRAIL relevant for its therapeutic applications.

Original languageEnglish
Pages (from-to)828-832
Number of pages5
JournalInvestigational New Drugs
Volume30
Issue number2
DOIs
Publication statusPublished - Apr 2012

Keywords

  • Pegylation
  • Signal transduction
  • TRAIL

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Oncology

Fingerprint Dive into the research topics of 'Pegylated TRAIL retains anti-leukemic cytotoxicity and exhibits improved signal transduction activity with respect to TRAIL'. Together they form a unique fingerprint.

  • Cite this